X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list-302014837.html
https://www.prnewswire.com/news-releases/antengene-announces-inclusion-of-xpovio-selinexor-in-2023-chinas-national-reimbursement-drug-list-302014837.html
https://www.prnewswire.com/news-releases/karyopharm-shares-data-at-ash-2023-showing-strong-svr-and-tss-durability-observed-from-phase-1-study-of-selinexor-60mg-and-ruxolitinib-in-jak-inhibitor-jaki-naive-myelofibrosis-patients-with-no-svr-or-tss-progressions-observed--302010754.html
https://www.prnewswire.com/news-releases/karyopharm-announces-clinical-trial-collaboration-with-bristol-myers-squibb-to-evaluate-novel-celmod-agent-cc--92480-mezigdomide-in-combination-with-selinexor-in-patients-with-relapsedrefractory-multiple-myeloma-301970837.html
https://www.biopharmadive.com/news/karyopharm-biotech-layoffs-restructuring-xpovio/689685/
https://www.prnewswire.com/news-releases/karyopharm-initiates-pivotal-phase-3-study-of-xpo1-inhibitor-selinexor-and-ruxolitinib-in-jak-inhibitor-jaki-naive-myelofibrosis-301864950.html
https://www.prnewswire.com/news-releases/menarini-group-shares-nexpovio-selinexor-subgroup-data-from-boston-trial-at-the-european-hematology-association-congress-highlighting-clinical-potential-in-relapsedrefractory-multiple-myeloma-301845994.html
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-plus-bortezomib-and-dexamethasone-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-301839510.html
https://www.prnewswire.com/news-releases/karyopharm-announces-presentation-of-updated-phase-1-selinexor-data-in-patients-with-treatment-naive-myelofibrosis-at-aacr-2023-301800719.html
https://www.prnewswire.com/news-releases/karyopharm-to-present-data-from-phase-1-study-of-selinexor-in-patients-with-treatment-naive-myelofibrosis-at-aacr-and-to-host-investor-webcast-on-april-18th-301797790.html
https://www.onclive.com/view/mhra-approves-selinexor-plus-bortezomib-dexamethasone-for-multiple-myeloma-following-1-prior-therapy
https://www.prnewswire.com/news-releases/karyopharm-and-menarini-group-receive-full-marketing-authorization-from-the-uk-medicines--healthcare-products-regulatory-agency-for-nexpovio-selinexor-in-combination-with-bortezomib-and-dexamethasone-for-the-treatment-of-adult-301751848.html
https://www.prnewswire.com/news-releases/karyopharm-announces-investor-and-analyst-event-at-ash-2022-on-selinexor-data-in-patients-with-treatment-naive-myelofibrosis-301694571.html
https://www.prnewswire.com/news-releases/karyopharm-announces-new-selinexor-data-in-myelofibrosis-and-multiple-myeloma-to-be-presented-at-ash-2022-301667668.html
https://www.biospectrumasia.com/news/26/21039/china-based-startup-antengene-accelerates-expansion-in-apac-region.html
https://en.prnasia.com/releases/apac/antengene-announces-xpovio-included-for-reimbursement-by-the-pbs-in-australia-for-the-treatment-of-patients-with-relapsed-and-or-refractory-multiple-myeloma-373795.shtml
https://ecancer.org/en/news/21951-researchers-discover-genes-that-predict-good-response-to-blood-cancer-therapy
https://www.prnewswire.com/news-releases/antengene-announces-first-patient-dosed-in-the-phase-iii-swatch-study-of-xpovio-selinexor-for-the-treatment-of-b-cell-non-hodgkin-lymphomas-301552624.html
https://www.prnewswire.com/news-releases/karyopharm-and-menarini-group-receive-positive-chmp-opinion-for-nexpovio-selinexor-for-the-treatment-of-patients-with-refractory-multiple-myeloma-301552114.html
https://www.prnewswire.com/news-releases/antengene-announces-commercial-availability-of-xpovio-selinexor-for-the-treatment-of-relapsedrefractory-multiple-myeloma-prescribed-for-the-first-time-across-mainland-china-301547596.html
https://www.prnewswire.com/news-releases/karyopharm-announces-xpovio-selinexor-data-to-be-presented-at-the-european-hematology-association-2022-hybrid-congress-301546251.html
https://www.prnewswire.com/news-releases/karyopharm-announces-selinexor-data-to-be-presented-at-the-2022-american-society-of-clinical-oncology-annual-meeting-301533856.html
https://www.prnewswire.com/news-releases/antengene-announces-xpovio-approved-by-the-tga-in-australia-for-the-treatment-of-relapsed-andor-refractory-multiple-myeloma-and-triple-class-refractory-multiple-myeloma-301498919.html
https://investors.karyopharm.com/2022-03-01-Karyopharm-Provides-U-S-Regulatory-Update-on-Selinexor-in-Advanced-or-Recurrent-Endometrial-Cancer
https://www.bioworld.com/articles/515869-karyopharm-plays-wild-card-with-xpovio-in-ec-pair-of-jacks-or-better?v=preview
https://www.prnewswire.com/news-releases/karyopharm-reports-strong-fourth-quarter-and-full-year-2021-financial-results-and-highlights-recent-company-progress-301477530.html
https://www.prnewswire.com/news-releases/karyopharm-announces-phase-3-siendo-study-meets-primary-endpoint-with-statistically-significant-increase-in-progression-free-survival-in-patients-with-advanced-or-recurrent-endometrial-cancer-301477528.html
https://www.prnewswire.com/news-releases/karyopharm-and-menarini-group-enter-into-exclusive-license-agreement-to-commercialize-nexpovio-selinexor-in-europe-and-other-key-global-territories-301449025.html
https://www.asiaone.com/business/karyopharm-and-menarini-group-enter-exclusive-license-agreement-commercialize-nexpovio
https://www.prnewswire.com/news-releases/antengene-presents-results-of-phase-1b-touch-trial-of-selinexor-for-the-treatment-of-t-and-nk-cell-lymphoma-at-the-2021-american-society-of-hematology-ash-annual-meeting-301443886.html
https://www.asiaone.com/business/antengene-announces-ind-approval-china-phase-iii-study-selinexor-atg-010-patients-non
https://www.prnewswire.com/news-releases/antengene-granted-ind-approval-in-china-for-the-phase-ib-study-of-atg-008-onatasertib-in-combination-with-atg-010-selinexor-in-patients-with-diffuse-large-b-cell-lymphoma-301413468.html
https://www.prnewswire.com/news-releases/karyopharm-announces-xpovio-selinexor-data-to-be-presented-at-the-european-hematology-association-2021-virtual-congress-301308491.html
https://investors.karyopharm.com/2021-06-03-Karyopharm-Announces-XPOVIO-R-selinexor-Is-Now-Available-in-Additional-Strength-Tablets
https://investors.karyopharm.com/2021-04-26-Karyopharm-Announces-European-Medicines-Agencys-Validation-of-its-Type-II-Variation-Marketing-Authorization-Application-for-NEXPOVIO-R-selinexor-in-Combination-with-Velcade-R-bortezomib-and-Dexamethasone-for-the-Treatment-of-Adult-Patients-with
https://investors.karyopharm.com/2021-04-19-Karyopharm-Announces-Publication-of-Health-Related-Quality-of-Life-Outcomes-from-Phase-3-SEAL-Study-of-Selinexor-in-Advanced-Unresectable-Dedifferentiated-Liposarcoma-in-Future-Oncology
https://www.prnewswire.com/news-releases/medivir-has-determined-the-starting-dose-for-the-next-part-of-the-phase-ib-study-with-miv-818-301271423.html
https://www.prnewswire.com/news-releases/karyopharm-receives-conditional-marketing-authorization-from-the-european-commission-for-nexpovio-selinexor-in-combination-with-dexamethasone-for-the-treatment-of-adult-patients-with-relapsed-and-or-refractory-multiple-myeloma-301257702.html
https://www.prnewswire.com/news-releases/antengene-announces-nda-for-atg-010-selinexor-granted-priority-review-by-chinas-nmpa-301234036.html
https://www.biospace.com/article/releases/karyopharm-receives-positive-chmp-opinion-for-nexpovio-selinexor-for-the-treatment-of-patients-with-refractory-multiple-myeloma/
https://www.prnewswire.com/news-releases/antengene-announces-the-acceptance-of-atg-010-selinexor-nda-by-the-nmpa-for-the-treatment-of-rrmm-301216226.html
https://www.biospace.com/article/releases/antengene-submits-nda-for-atg-010-selinexor-in-south-korea-for-rrmm-and-rrdlbcl/
https://www.prnewswire.com/news-releases/antengene-submits-nda-for-atg-010-selinexor-in-south-korea-for-rrmm-and-rrdlbcl-301199927.html
https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-selinexor-refractory-or-relapsed-multiple-myeloma
Market Place
Share 
